The application of CRISPR technology offers a transformative approach to CML treatment by effectively targeting and eliminating the BCR/ABL oncogene, which is crucial for leukemic cell survival. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.